Clay Siegall’s fight to counter cancer

Clay Siegall is the CEO and also chairman of the board at Seattle genetics. Siegall started the genetics company way back in the year 1998 and ever since he has been on the verge of coming up with special treatment drugs to counter several ailments related to cancer. Some of the drugs include Adcetris which is the company’s flagship drug. The drug is expected to treat the Hodgkin Lymphoma which is a cancer of the Lymph system.

Currently, the company boasts of having a market value of $10 billion dollars and a roaster of 900 employees. This alone makes it the leading biotech company in Washington. Siegall goes on to state that they are an emerging global multi-product oncology company that is on the staircase to be a global player. Siegall is a sign of commitment to this global market made a bid to spend $2 billion to commercialize a cancer drug that had been developed by the New Jersey Immuno medics. This could not be possible later on because a judge ruled out any possibilities of it happening since there was a struggle for power in the immunomedics board.

Seattle genetics sales trajectory is a forward trajectory though the company is yet to make some profit after 18 years. This could be changed with the company focusing on eleven drug types. Siegal confirms that their focus is on four of the drug types them including the Adcetris that was approved by the Food and Drug Administration (FDA). The drug is expected to act as a complement to the treatment of the Hodgkin lymphoma. The drug is on a trajectory to raise close to a billion dollars. The other drugs include number 33A poised to counter acute myeloid leukemia or the AML, and finally, 22ME that is aimed at bladder cancer.

Clays’ place in the spotlight has been possible because of the steadfast progress against cancer. He goes on to say that he loves making drugs but also admits that it is a path full of ups and downs.

Clay Siegall

Clay Siegall is the founder, president, CEO and also chairman at Seattle genetics. Under his leadership, the company has grown to build a diverse pipeline in the counter against cancer.

Before founding Seattle genetics, Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute in the years between 1991 and 1997. Other companies that he has worked with include: National Cancer Institute and also National Institutes of Health.

Siegall has a B.S in zoology from the University of Maryland and also a Ph. D in genetics from Washington University.

 

How Oncotarget Became One of the Leading Medical Journals in the Research World

Oncotarget is medical journal founded in 2010 by Dr. Mikhail Blagosklonny. This journal is a multidisciplinary platform that publishes papers on a weekly basis. Oncotarget is a peer reviewed journal with free-access.

The leadership of Oncotarget

Dr. Mikhail Blagosklonny founded this journal together his colleague Andrei V. Gudkov from the Roswell Park Cancer Institute. These two professionals serve as the senior editors of Oncotarget. Dr. Mikhail is a cancer specialist and a professor at the famed Roswell Park Cancer Institute. This scientist has published various research papers in Oncotarget and other journals. He has authored close to 270 articles and has more than 25,000 citations. Dr. Mikhail’s recent hypothesis is that Rapamycin could be used to extend a person’s life. Some of the other editors who work at Oncotarget include:

• Frederick Alt of Harvard Medical School

• Ronald A. DePinho of the University of Texas

• Brain J. Druker of Oregon Health Science, Portland

• Arthur B. Pardee of Harvard University

• Bert Vogelstein, Johns Hopkins University

Andrei V. Gudkov is a researcher at the Roswell Park Cancer Institute. He is the chairman of the division of Cell Stress Biology. He helped Dr. Mikhail set up Oncotarget with the aim of promptly disseminating research findings to the general public. He has published and edited various articles that were later posted on Oncotarget. Andrei has published a total of 135 papers and has more than 27 patented products. His efforts and those of his colleague are responsible for the success of this peer-reviewed medical journal. This journal is in charge of revealing immense knowledge on various topics and discoveries. Under their management, Oncotarget has been able to stand out as a journal that promotes both local and international research works.

Materials published by Oncotarget

Aside from oncology, Oncotarget publishes other papers in the fields of endocrinology, pharmacology, cell biology, cardiology, metabolism, and neuroscience. Additionally, Oncotarget also publishes articles on aging and gerotarget. The Code of Conduct for Journal Publishers and COPE Code of Conduct and Best Practice Guidelines for Journal Editors is the one that governs Oncotarget. Apart from research papers, Oncotarget also publishes medical articles and book chapters.

To know more visit @: www.linkedin.com/in/mikhail-blagosklonny-91abb531/